Histopathological and immunohistochemical parameters of breast cancer cases analyzed in a reference laboratory

Authors

Keywords:

breast cancer, immunohistochemistry, pathology

Abstract

Objective: To determine the histopathological and immunohistochemical parameters of breast cancer cases treated in Belém, state of Pará, Brazil. Method: This is a cross-sectional, retrospective and observational study in which samples from 278 patients were analyzed. In the histopathological analysis were considered, among other factors, the differentiation and histopathological classification of the tumor, based on the WHO classification. As for immunohistochemistry, the presence and intensity of expression of the cell proliferation antigen Ki-67, gene product of HER2, and estrogen and progesterone receptors were evaluated. Then, the tumors were classified into luminal A, luminal B, luminal hybrid, HER2 group, and basal-like. Results: The most common histological subtypes were invasive carcinoma of no special type (88.7%), carcinoma in situ (5.5%), and invasive mucinous carcinoma (2.9%). The most common immunohistochemical subtypes were luminal A (26.1%), basal-like (23.6%), and luminal B (23.2%). We also found a statistically significant inversely proportional relationship (p<0.01) of hormone receptor expression with nuclear grade. Conclusion: The results show the importance of immunohistochemical analysis for staging, as well as for the therapeutic decision of each patient. However, further studies with a larger sample must be performed for more effective analysis of the general population.

Downloads

Download data is not yet available.

Author Biographies

Marina Crespo Soares, Universidade do Estado do Pará

Department of Medicine, Universidade do Estado do Pará – Belém (PA), Brazil.

Isabela Juliana Manfredo Rodrigues, Universidade do Estado do Pará

Department of Medicine, Universidade do Estado do Pará – Belém (PA), Brazil.

Igor Cerejo Tavares da Silva de Almeida, Universidade do Estado do Pará

Department of Medicine, Universidade do Estado do Pará – Belém (PA), Brazil.

João Victor Pereira Assunção

Department of Medicine, Universidade do Estado do Pará – Belém (PA), Brazil.

Andrew Moraes Monteiro, Universidade do Estado do Pará

Department of Medicine, Universidade do Estado do Pará – Belém (PA), Brazil.

Leônidas Braga Dias Júnior, Universidade do Estado do Pará

Department of Medicine, Universidade do Estado do Pará – Belém (PA), Brazil.

References

Geyer FC, De Nigro MV. Tipos histológicos especiais de câncer de mama. Rev Onco&. 2013;15:28-32.

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206-23. https://doi.org/10.1093/annonc/mdt303

Viale G. The current state of breast cancer classification. Ann Oncol. 2012;23(Supl. 10):x207-10. https://doi.org/10.1093/annonc/mds326

Pachnicki JPA, Czeczko NG, Tuon F, Cavalcanti TS, Malafaia AB, Tuleski AM. Avaliação imunoistoquímica dos receptores de estrogênio e progesterona no câncer de mama, pré e pós-quimioterapia neoadjuvante. Rev Col Bras. 2012;39(2):86-92. http://dx.doi.org/10.1590/S0100-69912012000200002

Cintra JRD, Teixeira MTB, Diniz RW, Gonçalves Junior H, Florentino TM, Freitas GF, et al. Perfil imuno-histoquímico e variáveis clinicopatológicas no câncer de mama. Rev Assoc Med Bras. 2012;58(2):178-87. http://dx.doi.org/10.1590/S0104-42302012000200013

Becker RG, Galia CR, Morini S, Viana CR. Expressão imuno-histoquímica das proteínas vegf e her-2 em biópsias de osteossarcoma. Acta Ortop Bras. 2013;21(4):233-83.

American Joint Committee on Cancer (AJCC). Cancer Staging Manual. 6ª ed. AJCC; 2002.

Lebeau A, Kriegsmann M, Burandt E, Sinn HP. [Invasive breast cancer: the current WHO classification]. Pathologe. 2014;35(1):7-17. https://doi.org/10.1007/s00292-013-1841-7

Pérez-Rodríguez G. Prevalence of breast cancer sub-types by immunohistochemistry in patients in the Regional General Hospital 72, Instituto Mexicano del Seguro Social. Cir Cir. 2015;83(3):193-8. https://doi.org/10.1016/j.circir.2015.05.003

Mendoza del Solar G, Echegaray A, Caso C. Perfil inmunohistoquímico del cáncer de mama en pacientes de un hospital general de Arequipa, Perú. Rev Med Hered. 2015;26(1):31-4.

Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-95. https://doi.org/10.1200/JCO.2009.25.6529

Cherbal F, Gaceb H, Mehemmai C, Saiah I, Bakour R, Rouis AO, et al. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study. Breast Dis. 2015;35(2):95-102. https://doi.org/10.3233/BD-150398

Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, Bacchi CE. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. BMC Womens Health. 2014;14:102. https://doi.org/10.1186/1472-6874-14-102

Sánchez-Muñoz A, Román-Jobacho A, Pérez-Villa L, Sánchez-Rovira P, Miramón J, Pérez D, et al. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization. Oncology. 2012;83(4):228-33. https://doi.org/10.1159/000341537

Fourati A, Boussen H, El May MV, Goucha A, Dabbabi B, Gamoudi A, et al. Descriptive analysis of molecular subtypes in Tunisian breast cancer. Asia Pac J Clin Oncol. 2014;10(2):e69-74. https://doi.org/10.1111/ajco.12034

Hagemann IS. Molecular Testing in Breast Cancer: A Guide to Current Practices. Arch Pathol Lab Med. 2016;140(8):815-24. https://doi.org/10.5858/arpa.2016-0051-RA

Meattini I, Bicchierai G, Saieva C, De Benedetto D, Desideri I, Becherini C, et al. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature. Eur J Surg Oncol. 2017;43(4):642-8. https://doi.org/10.1016/j.ejso.2016.10.025

Caldarella A, Buzzoni C, Crocetti E, Bianchi S, Vezzosi V, Apicella P, et al. Invasive breast cancer: a significant correlation between histological types and molecular subgroups. J Cancer Res Clin Oncol. 2013;139(4):617-23. https://doi.org/10.1007/s00432-012-1365-1

Smaniotto ACR, Oliveira HR, Botogoski SR, Nalevaiko JZ, Costa L, Damião N. Perfil clínico, histológico e biológico de pacientes submetidos à biópsia do linfonodo sentinela por câncer de mama. Arq Med Hosp Fac Cienc Med Santa Casa São Paulo. 2013;58(3):121-6.

Dayal A, Shah JR, Kothari S, Patel SM. Correlation of Her-2/neu Status With Estrogen, Progesterone Receptors and Histologic Features in Breast Carcinoma. Ann Pathol Laboratory Medicine. 2016;3(5 Supl.):477-83.

Azizun-Nisa, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR & HER-2/neu (C-erb B 2) Reactivity Pattern with Histologic Grade, Tumor Size and Lymph Node Status in Breast Cancer. Asian Pac J Cancer Prev. 2008;9(4):553-6.

Siadati S, Sharbatdaran M, Nikbakhsh N, Ghaemian N. Correlation of ER, PR and HER-2/Neu with other Prognostic Factors in Infiltrating Ductal Carcinoma of Breast. Iran J Pathol. 2015;10(3):221-6.

Wang B, Wang X, Wang J, Xuan L, Wang Z, Wang X, et al. Expression of Ki67 and clinicopathological features in breast cancer. Zhonghua Zhong Liu Za Zhi. 2014;36(4):273-5.

Narbe U, Bendahl PO, Grabau D, Rydén L, Ingvar C, Fernö M. Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor. SpringerPlus. 2014;3:70. https://doi.org/10.1186/2193-1801-3-70

Arantes Júnior JC. Perfis Histopatológico e Imuno-histoquímico do câncer de mama: Comparação entre lesões palpáveis e não-palpáveis [tese]. Botucatu: Universidade Estadual Paulista "Júlio de Mesquita Filho"; 2006.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. Correlation of Her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J. 2005;11(4):278-80. https://doi.org/10.1111/j.1075-122x.2005.21463.x

Tokatli F, Altaner S, Uzal C, Ture M, Kocak Z, Uygun K, et al. Association of HER-2 over expression with the number of involved axillary lymph nodes in human receptor positive breast cancer patients. Exp Oncol. 2005;27(2):145-9.

Abdollahi A, Sheikhbahaei S, Safinejad S, Jahanzad I. Correlation of ER, PR, HER- 2 and P53 Immunoreactions with Clinico-Pathological Features in Breast Cancer. Iran J Pathol. 2013;8(3):147-52.

Downloads

Published

2020-04-12

How to Cite

Soares, M. C., Rodrigues, I. J. M., Almeida, I. C. T. da S. de, Assunção, J. V. P., Monteiro, A. M., & Dias Júnior, L. B. (2020). Histopathological and immunohistochemical parameters of breast cancer cases analyzed in a reference laboratory. Mastology, 30, 1–7. Retrieved from https://revistamastology.emnuvens.com.br/revista/article/view/345

Issue

Vol. 30 (2020)

Section

Original Articles

License

Copyright (c) 2020 Marina Crespo Soares, Isabela Juliana Manfredo Rodrigues, Igor Cerejo Tavares da Silva de Almeida, João Victor Pereira Assunção, Andrew Moraes Monteiro, Leônidas Braga Dias Júnior

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.